Published: January 5, 2024
GBI’s Vice President of Commercial Operations, Amita Quadros, Ph.D., has participated in a Pharma Almanac’s 2023 roundtable discussion.
The topic of discussion was “What Do You Think Was The Single Most Consequential Event Or Result In Pharma/Biopharma In 2023?”:
“While it’s difficult to write about a single most consequential event or result in the pharma/biopharma industry in 2023, since a lot has happened and it continues to evolve, some notable topics are as follows:
While it’s difficult to write about a single most consequential event or result in the pharma/biopharma industry in 2023, since a lot has happened and it continues to evolve, some notable topics are as follows:
- Continuous development of new and innovative drugs using technologies like artificial intelligence and machine learning are being implemented in a number of pharma/biopharma and larger CDMOs.
- The COVID-19 pandemic has brought to light supply chain challenges, resulting in companies building more resilient and diversified supply chains.
- The overall funding this year has been very bleak, resulting in quite a number of mergers and acquisitions in our industry. Larger companies with deep pockets have made strategic partnerships to enhance their product portfolios or expand their market presence.
- The European Commission revised Annex 1 – Manufacture of Sterile Medicinal Products as of August 25, 2023, which means that pharmaceutical manufacturers are required to implement the GMP regulation into cleaning and biodecontamination procedures for these products.
- Opioid addiction has significantly increased. The Controlled Substances Act places all substances into one of five schedules based upon the substance’s accepted medical use, potential for abuse, safety or dependence liability. GBI, a CDMO, has a Schedule II DEA license and is working actively with clients to manufacture biologic vaccines.”
